Evidence map›Paper›PMID 39757767›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

RTN4IP1 Contributes to ESCC via Regulation of Amino Acid Transporters.

Huifang Wei, Dengyun Zhao, Yafei Zhi, Qiong Wu, Jing Ma, Jialuo Xu, Tingting Liu, Jing Zhang, Penglei Wang, Yamei Hu and 9 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. RTN4IP1 Contributes to ESCC via Regulation of Amino Acid Transporters.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Huifang WeiDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Dengyun ZhaoDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Chest Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Yafei ZhiDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Qiong WuDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Jing MaDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China.
Jialuo XuDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China.
Tingting LiuDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Jing ZhangDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Penglei WangDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Yamei HuDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Xinyu HeDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Fangqin GuoDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Ming JiangChina-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Dandan ZhangChina-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Wenna NieChina-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Ran YangChina-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Tongjin ZhaoDepartment of Pathophysiology, School of Basic Medical Sciences, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, 450000, China.
Zigang DongDepartment of Pathophysiology, School of Basic Medical Sciences, The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, State Key Laboratory of Esophageal, Cancer Prevention and Treatment, Provincial Cooperative Innovation Center for Cancer Chemoprevention, China-US (Henan) Hormel Cancer Institute, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, 450000, China.
Kangdong LiuDepartment of Pathophysiology, School of Basic Medical Sciences, The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, State Key Laboratory of Esophageal, Cancer Prevention and Treatment, Provincial Cooperative Innovation Center for Cancer Chemoprevention, China-US (Henan) Hormel Cancer Institute, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, 450000, China.ORCID https://orcid.org/0000-0002-4425-5625

Funding

National Natural Science Foundations of China 81872335National Natural Science Foundations of China 82303119National Natural Science Foundations of China 82472998Scientific and Technological Project in Henan Province 222102310057
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) accounts for about 90% of esophageal cancer cases. The lack of effective therapeutic targets makes it difficult to improve the overall survival of patients with ESCC. Reticulon 4 Interacting Protein 1 (RTN4IP1) is a novel mitochondrial oxidoreductase. Here, a notable upregulation of RTN4IP1 is demonstrated, which is associated with poor survival in patients with ESCC. RTN4IP1 depletion impairs cell proliferation and induces apoptosis of ESCC cells. Furthermore, c-Myc regulates RTN4IP1 expression via iron regulatory protein 2 (IRP2) at the post-transcriptional level. Mechanistically, RTN4IP1 mRNA harbors functional iron-responsive elements (IREs) in the 3' UTR, which can be targeted by IRP2, resulting in increased mRNA stability. Finally, RTN4IP1 depletion abrogates amino acid uptake and induces amino acid starvation via downregulation of the amino acid transporters SLC1A5, SLC3A2, and SLC7A5, indicating a possible pathway through which RTN4IP1 contributes to ESCC carcinogenesis and progression. In vivo studies using cell-derived xenograft and patient-derived xenograft mouse models as well as a 4-nitroquinoline 1-oxide-induced ESCC model in esophageal-specific Rtn4ip1 knockout mice demonstrate the essential role of RTN4IP1 in ESCC development. Thus, RTN4IP1 emerges as a key cancer-promoting protein in ESCC, suggesting therapeutic RTN4IP1 suppression as a promising strategy for ESCC treatment.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaAmino Acid Transport System ASCAnimalsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceAmino Acid Transport System ASCAmino acid transportersc‐MycESCCIron regulatory proteinsIron responsive elementRTN4IP1

Identifiers

PMID39757767
PMCPMC11848606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.